John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 11,700 shares at $179.75 ($2.1M) on 2021-03-01, disclosed to the SEC on 2021-03-03.
Open-market sale of $2.1M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $178.80 | 900 | $161K | 7.5% |
| 2 | $179.75 | 1,317 | $237K | 11.0% |
| 3 | $179.75 | 1,317 | $237K | 11.0% |
| 4 | $180.95 | 500 | $90K | 4.2% |
| 5 | $182.02 | 700 | $127K | 5.9% |
| 6 | $183.94 | 600 |
| $110K |
| 5.1% |
| 7 | $184.93 | 400 | $74K | 3.4% |
| 8 | $186.14 | 2,883 | $537K | 25.0% |
| 9 | $186.14 | 2,883 | $537K | 25.0% |
| 10 | $186.85 | 200 | $37K | 1.7% |
| Total | $183.53 avg | 11,700 | $2.1M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |